Barclays analyst Luke Sergott lowered the firm’s price target on Thermo Fisher to $625 from $660 and keeps an Overweight rating on the shares. The macro environment "continues to dominate the conversation" heading into the Q1 results for the life science tools and diagnostics sector, the analyst tells investors in a research note. The firm expects results in line with the "relatively light" Q1 guides with "no risk clearings yet." It still believes in the recovery and expects some relief in Q2 for a better second half of the year setup.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on TMO:
- ‘The End of the Bear Market May Be in Sight,’ Says Morgan Stanley. Here Are 3 Stocks the Banking Giant Likes for Long-Term Growth
- Thermo Fisher opens cell therapy facility at UCSF
- Stevanato Group announces partnership with Thermo Fisher
- Thermo Fisher CEO sells $8.24M in common stock
- Gensight Biologics price target lowered to EUR 13 from EUR 15 at Chardan